CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 184 enrolled
Drug / intervention
Diclofenac Na gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00601640
NCT00601640Phase 2Completed
CompareCT.gov

Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm

University of Arizona·interventional·Posted Jan 28, 2008·Updated Mar 23, 2017

In Brief

A Phase 2 clinical trial evaluating Diclofenac Na gel and Eflornithine HCL ointment for Other Benign Neoplasm of Skin, Unspecified. Completed, enrolled 184 participants across 3 sites.

Detailed Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared with diclofenac, given alone or together, in treating patients with sun-damaged skin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOther Benign Neoplasm of Skin, Unspecified
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 28, 2008
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18.4 years ago

Interventions

Diclofenac Na geldrug

Given topically twice daily on days 1-90

Eflornithine HCL ointmentdrug

Given topically twice daily on days 1-90